Subodh Verma




Please note: Dr. Verma will not take students in summer.

Dr. Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the current Canada Research Chair in Cardiovascular Surgery, having previously served as the Canada Research Chair in Atherosclerosis (2007-2017). Dr. Verma was recently awarded the 2021 Lister Prize in Surgery from the University of Toronto in recognition of his outstanding and continuing productivity of international stature. He is a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars, Artists and Scientists, Royal Society of Canada. According to Google Scholar in April 2021, Dr. Verma has an h-index of 100 and his work has been cited over 50,000 times.

Dr. Verma has published extensively in highly impactful journals like the NEJM, Lancet, Circulation, JACC, Nature, and JCI. He is an Associate Editor of the European Heart Journal. Dr. Verma is an active contributor to Canadian clinical practice guidelines and co-authored the recently updated recommendations for atrial fibrillation, antiplatelet therapy, diabetes, and heart failure; he was a member of the 2018 AATS consensus guidelines committee on bicuspid aortic valve-related aortopathy. Dr. Verma has served in various capacities on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.

Dr. Verma had/has leadership roles on 10 contemporary global heart failure trials – several of which have let to paradigm changes in how individuals all around the world who live with diabetes and heart failure are now managed. He founded and oversees the CardioLink platform at St Michael’s Hospital that is conducting cardiometabolic and surgically oriented RCTs and translational studies.

Dr. Verma leads a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. His research has yielded 2 United States patents and is supported by several national peer-reviewed grants.


Recent Publications

  1. Butler, J, Filippatos, G, Jamal Siddiqi, T, Pedro Ferreira, J, Brueckmann, M, Bocchi, E et al.. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction. Circulation. 2022; :101161CIRCULATIONAHA122059755. doi: 10.1161/CIRCULATIONAHA.122.059755. PubMed PMID:36098051 .
  2. Butt, JH, Kondo, T, Jhund, PS, Comin-Colet, J, de Boer, RA, Desai, AS et al.. Dapagliflozin, atrial fibrillation, and heart failure with mildly reduced or preserved ejection fraction in DELIVER. J Am Coll Cardiol. 2022; :. doi: 10.1016/j.jacc.2022.08.718. PubMed PMID:36041668 .
  3. Solomon, SD, McMurray, JJV, Claggett, B, de Boer, RA, DeMets, D, Hernandez, AF et al.. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387 (12):1089-1098. doi: 10.1056/NEJMoa2206286. PubMed PMID:36027570 .
  4. Docherty, KF, Welsh, P, Verma, S, De Boer, RA, O'Meara, E, Bengtsson, O et al.. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. Circulation. 2022; :101161CIRCULATIONAHA122060511. doi: 10.1161/CIRCULATIONAHA.122.060511. PubMed PMID:35971840 .
  5. Mancini, GBJ, O'Meara, E, Zieroth, S, Bernier, M, Cheng, AYY, Cherney, DZI et al.. 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. Can J Cardiol. 2022;38 (8):1153-1167. doi: 10.1016/j.cjca.2022.04.029. PubMed PMID:35961754 .
  6. Hibino, M, Pandey, AK, Chan, V, Mazer, CD, Rumman, R, Dhingra, NK et al.. Risk Factors for Postrepair Elevated Mitral Gradient: A Post-hoc Analysis of a Randomized Trial. Ann Thorac Surg. 2022; :. doi: 10.1016/j.athoracsur.2022.05.053. PubMed PMID:35779599 .
  7. Gaba, P, Bhatt, DL, Mason, RP, Miller, M, Verma, S, Steg, PG et al.. Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT. J Clin Lipidol. ;16 (4):389-402. doi: 10.1016/j.jacl.2022.05.067. PubMed PMID:35773147 .
  8. Hibino, M, Dhingra, NK, Chan, V, Mazer, CD, Teoh, H, Quan, A et al.. Stage-based approach to predict left ventricular reverse remodeling after mitral repair. Clin Cardiol. 2022;45 (9):921-927. doi: 10.1002/clc.23879. PubMed PMID:35748086 PubMed Central PMC9451668.
  9. Pandey, AK, Bhatt, DL, Cosentino, F, Marx, N, Rotstein, O, Pitt, B et al.. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Eur Heart J. 2022;43 (31):2931-2945. doi: 10.1093/eurheartj/ehac299. PubMed PMID:35713973 .
  10. Vervoort, D, An, KR, Elbatarny, M, Tam, DY, Quastel, A, Verma, S et al.. Dealing With the Epidemic of Endocarditis in People Who Inject Drugs. Can J Cardiol. 2022;38 (9):1406-1417. doi: 10.1016/j.cjca.2022.06.004. PubMed PMID:35691567 .
Search PubMed

Affiliations & Other Activities

  • Cardiac Surgeon, Division of Cardiology , St. Michael’s Hospital
  • Professor of Surgery and Pharmacology & Toxicology, University of Toronto
  • Canada Research Chair in Cardiovascular Surgery